Skip to content

PENG Block and Delirium After Hip Arthroplasty

Effect of Pericapsular Nerve Group (PENG) Block Added to Spinal Anesthesia on Postoperative Delirium in Older Adults Undergoing Primary Total Hip Arthroplasty: A Prospective, Randomized, Assessor-Blinded Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07449468
Enrollment
180
Registered
2026-03-04
Start date
2026-04-01
Completion date
2027-06-30
Last updated
2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Osteoarthritis

Brief summary

Postoperative delirium is a common and serious complication in older adults undergoing total hip arthroplasty, associated with prolonged hospitalization, increased morbidity, delayed rehabilitation, and long-term cognitive decline. Modifiable perioperative risk factors include uncontrolled postoperative pain, opioid consumption, impaired early mobilization, and systemic inflammatory response. The Pericapsular Nerve Group (PENG) block is a regional anesthesia technique targeting the sensory innervation of the anterior hip capsule and may provide effective analgesia while preserving motor function. Improved pain control and opioid reduction may decrease the incidence of postoperative delirium. This prospective, randomized, parallel-group controlled trial aims to evaluate whether the addition of ultrasound-guided PENG block to spinal anesthesia reduces the incidence of postoperative delirium within 72 hours after primary total hip arthroplasty in patients aged 65 years or older. Delirium will be assessed using the Confusion Assessment Method (CAM) by blinded outcome assessors. Secondary outcomes include postoperative opioid consumption, pain intensity (NRS), time to first rescue opioid, postoperative nausea and vomiting, time to mobilization, block-related adverse events, and perioperative inflammatory indices (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio). The study will enroll 144 patients randomized 1:1 to spinal anesthesia alone or spinal anesthesia plus PENG block.

Detailed description

Postoperative delirium is a frequent and serious complication in older adults undergoing major orthopedic surgery, including total hip arthroplasty. Its incidence in this population ranges from 10% to 30% and is associated with prolonged hospital stay, increased healthcare costs, delayed functional recovery, long-term cognitive impairment, and increased mortality. Among modifiable perioperative risk factors, inadequate pain control, higher opioid consumption, postoperative nausea and vomiting, sleep disturbances, delayed mobilization, and systemic inflammatory response play an important role. Regional anesthesia techniques may reduce delirium risk by improving analgesia, decreasing opioid requirements, and attenuating surgical stress and inflammatory response. The Pericapsular Nerve Group (PENG) block is an ultrasound-guided regional anesthesia technique targeting the articular branches supplying the anterior hip capsule. It has been shown to provide effective analgesia after hip surgery while largely preserving quadriceps motor function, potentially facilitating early mobilization. This study is a prospective, randomized, parallel-group controlled trial designed to evaluate whether the addition of ultrasound-guided PENG block to spinal anesthesia reduces the incidence of postoperative delirium in patients aged 65 years or older undergoing primary elective total hip arthroplasty. Eligible patients (ASA II-III) will be randomized in a 1:1 ratio to receive: spinal anesthesia with standard multimodal postoperative analgesia (control group), or spinal anesthesia combined with ultrasound-guided PENG block plus standard multimodal postoperative analgesia (intervention group). Randomization will be computer-generated with concealed allocation. Outcome assessors evaluating delirium and functional endpoints will be blinded to group assignment. The anesthesiologist performing the block cannot be blinded but will not participate in postoperative outcome assessment. The primary endpoint is the incidence of postoperative delirium within 72 hours after surgery, assessed at least once daily using the Confusion Assessment Method (CAM) by trained, blinded personnel. Documentation review for delirium-related symptoms and use of antidelirium medications will complement, but not replace, structured CAM assessment. Secondary endpoints include cumulative opioid consumption during the first 48 postoperative hours (expressed as morphine milligram equivalents), pain intensity at rest and during movement (Numeric Rating Scale), time to first rescue opioid administration, incidence of postoperative nausea and vomiting, time to first mobilization, and block-related adverse events. Additionally, perioperative inflammatory response will be explored using routinely collected complete blood count parameters. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) will be calculated at predefined time points (baseline, 24 hours, and 48 hours postoperatively). Exploratory analyses will assess associations between these inflammatory indices and postoperative delirium. The planned sample size is 144 patients (72 per group), calculated to detect a clinically relevant reduction in delirium incidence with 80% power and a two-sided alpha of 0.05, accounting for potential dropouts. The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice principles. Written informed consent will be obtained from all participants prior to enrollment.

Interventions

DRUGsham block with 0.9% sodium chloride

After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20ml of 0.9% sodium chloride

After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20 ml of 0.2% ropivacaine

Sponsors

Poznan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
75 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 75 years * Scheduled for elective primary total hip arthroplasty * Planned spinal anesthesia * ASA physical status II-III * Ability to provide written informed consent * Ability to communicate and reliably assess pain using the Numeric Rating Scale (NRS) * Expected postoperative hospitalization ≥ 72 hours

Exclusion criteria

* Pre-existing delirium, acute psychosis, or active major psychiatric disorder * Documented severe dementia or inability to provide informed consent * Severe hearing or visual impairment preventing reliable CAM assessment * Contraindications to regional anesthesia (e.g., coagulopathy according to institutional standards, infection at the injection site, allergy to local anesthetics) * Pre-existing neurological deficits of the operative lower limb are interfering with assessment * Chronic opioid use (\>30 mg morphine milligram equivalents per day for \>2 weeks prior to surgery) * Severe renal impairment (eGFR \<30 mL/min/1.73 m²) * Severe hepatic insufficiency * Participation in another interventional clinical trial within 30 days * Any other condition that, in the investigator's judgment, may interfere with study participation or protocol adherence

Design outcomes

Primary

MeasureTime frameDescription
Incidence of postoperative delirium12 hours after surgeryIncidence of postoperative delirium within 72 hours after surgery, defined as at least one positive Confusion Assessment Method (CAM) assessment (CAM+) at any of the prespecified postoperative time points. CAM will be administered by trained assessors blinded to group allocation. The primary endpoint will be recorded as a binary outcome (delirium: yes/no)

Secondary

MeasureTime frameDescription
Incidence of Postoperative Delirium24 hours after surgeryIncidence of postoperative delirium within 72 hours after surgery, defined as at least one positive Confusion Assessment Method (CAM) assessment (CAM+) at any of the prespecified postoperative time points. CAM will be administered by trained assessors blinded to group allocation. The primary endpoint will be recorded as a binary outcome (delirium: yes/no)
Cumulative Postoperative Opioid Consumption (MME)48 hours after surgeryTotal opioid consumption during the first 48 hours after surgery, converted to morphine milligram equivalents (MME). Includes all rescue opioids administered intravenously or orally
Postoperative Pain Intensity (NRS)4 hours after surgeryPain intensity assessed using the 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) at rest and during movement.
Time to First Rescue Opioid Administration48 hours after surgeryTime (in hours) from arrival in the postoperative recovery area to the first administration of rescue opioid analgesia.
Incidence of Postoperative Nausea and Vomiting (PONV)24 hours after surgeryOccurrence of nausea and/or vomiting requiring pharmacological treatment during the early postoperative period.
Time to First Mobilization72 hours after surgeryTime (in hours) from the end of surgery to first assisted mobilization (e.g., standing or ambulation with physiotherapist support).
Systemic Inflammation Response Index (SIRI)12 hours after surgerySystemic Inflammation Response Index (SIRI) is used as a composite marker of systemic inflammatory activation. It is calculated from peripheral venous blood samples using the formula: SIRI = (Neutrophil count × Monocyte count) / Lymphocyte count All parameters are obtained from routine complete blood count (CBC) analysis and expressed in ×10⁹/L. SIRI reflects the interaction between innate immune activation (neutrophils and monocytes) and adaptive immune suppression (lymphocytes). Higher SIRI values indicate greater systemic inflammatory response.

Countries

Poland

Contacts

CONTACTMalgorzata Reysner, MD PhD
mreysner@ump.edu.pl+48 61 8320122

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026